Biotech’s TROP2 antibody drug conjugate sac-TMT for marketing in second indication: Chengdu, China Wednesday, March 12, 2025, 11:00 Hrs [IST] Sichuan K ...
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company's trophoblast cell-surface antigen 2 (TROP2)-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan ...
Chinese researchers have achieved a significant breakthrough by efficiently creating monkey blastoids using stem cells, ...
Despite these advancements, the team acknowledged that further optimization is needed, particularly in improving the functionality of trophoblast cells within the blastoid capsules. Future ...
Cardinal Health announced today that its Board of Directors has elected Robert Musslewhite, former Chief Executive Officer of Definitive Healthcare Corp., and Sudhakar Ramakrishna, President and Chief ...
A study in Reproductive and Developmental Medicine links elevated levels of the KLF12 protein to impaired placental ...
The full audited consolidated financial statements as of and for the year ended December 31, 2024, can be found in BioNTech's Annual Report on Form 20-F filed today with the United States Securities ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback